文献速递前列腺癌

新型含溴结构域和超末端结构域抑制剂联合化疗治疗去势抵抗性前列腺癌的疗效

Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2019-08-09

本研究在体外细胞实验和22Rv1前列腺癌小鼠移植瘤模型中,评估了两种临床阶段BET抑制剂INCB054329和INCB057643单用及联合多西他赛、奥拉帕利或卡铂的活性。结果显示两种BET抑制剂单药均有显著活性,INCB057643与各化疗药联合在体外呈协同/相加作用,在体内低强度给药方案下大幅增强多西他赛、卡铂和奥拉帕利的抗肿瘤活性。

要点

  • INCB054329和INCB057643单药在前列腺癌细胞系及22Rv1移植瘤中均有显著活性。
  • INCB057643与多西他赛、奥拉帕利或卡铂联合在体外呈协同/相加作用。
  • 低强度给药方案的INCB057643在22Rv1移植瘤中大幅增强多西他赛、卡铂和奥拉帕利的抗肿瘤活性。

核心结论

  • 这些结果首次提供证据表明BET抑制剂与非雄激素受体靶向治疗联合可用于转移性去势抵抗性前列腺癌的治疗获益。

研究设计与样本

  • 体外采用MTT、克隆形成、前列腺球和流式细胞术检测药物活性。
  • 体内采用22Rv1前列腺癌小鼠移植瘤模型评估药物活性。
  • 细胞生长数据计算最大效应和50%抑制浓度,联合治疗按Chou-Talalay法计算联合指数。
  • 体内监测肿瘤大小(T/Ci%)、重量(T/Cd%)、倍增时间和小鼠体重变化。
  • 统计显著性采用单因素方差分析后行Student-Newman-Keuls或Turkey事后检验。

主要发现

  • INCB054329和INCB057643单药在人前列腺癌细胞系和22Rv1移植瘤中均有显著活性。
  • INCB057643与多西他赛、奥拉帕利或卡铂中任一药物联合在体外呈协同/相加作用。
  • INCB057643采用低强度给药方案与多西他赛、卡铂或奥拉帕利联合,在22Rv1移植瘤中大幅增强抗肿瘤活性。

临床怎么用

  • 作者认为这些结果首次提供证据表明BET抑制剂与非雄激素受体靶向治疗联合可用于转移性去势抵抗性前列腺癌的治疗获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy is the treatment of choice for metastatic castration-resistant prostate cancer (mCRPC) nonresponsive to androgen receptor-targeted therapies. Nevertheless, the impact of chemotherapy on patient survival is limited and clinical outcome remain dismal. Bromodomain and extraterminal inhibitors (BETis) are attractive therapeutic agents and currently in clinical trials to be tested for their efficacy in prostate cancer patients. OBJECTIVE: In this study, we evaluated the activity of two clinical stage BETis, INCB054329 and INCB057643, alone and in combination with chemotherapeutics used for the treatment of mCRPC. DESIGN, SETTING, AND PARTICIPANTS: Drug activity was evaluated in vitro by MTT, clonogenic, prostato-sphere, and flow cytometry assays. The activity in vivo was evaluated in mice bearing prostate tumor (22Rv1) xenografts. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cell growth data were analyzed to determine the maximum effect and the concentration that reduces by 50%. For concomitant treatments, the combination index was determined according to the Chou-Talalay method. For in vivo activity, changes in tumor size (T/Ci%), weight (T/Cd%), doubling time, and mouse body weight were monitored. Statistical significance was determined by one-way analysis of variance followed by a Student-Newman-Keuls or Turkey a posteriori test. RESULTS AND LIMITATIONS: INCB054329 and INCB057643 had significant activity as single agents in human prostate cancer cell lines and 22Rv1 tumor xenografts. Combined treatment with INCB057643 and any of docetaxel, olaparib, or carboplatin was synergistic/additive in vitro. Notably, INCB057643, given with a low-intensity dosing schedule, greatly enhanced the anti-tumor activity of docetaxel, carboplatin, and olaparib in 22Rv1 tumor xenografts. CONCLUSIONS: Collectively, these results provide the first evidence of the therapeutic benefit obtainable by combining BETis with non-androgen receptor-targeted therapies for the treatment of mCRPC. PATIENT SUMMARY: Chemotherapy has limited efficacy in patients with metastatic castration-resistant prostate cancer. This study provides evidence of enhanced efficacy of clinically used chemotherapeutics when given in combination with the bromodomain and extraterminal inhibitor INCB057643, expanding the horizon of the current options for the treatment of prostate cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Vázquez R, Civenni G, Kokanovic A, et al. Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer. Eur Urol Oncol. 2019. PMID: 31402217. doi:10.1016/j.euo.2019.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。